Антикоагулянтные, противовоспалительные, противовирусные и противоопухолевые свойства гепаринов

Наши знания относительно химической структуры гепарина и его производных, а также всей палитры их свойств, включая биологические свойства в плазме крови, на клеточной поверхности и во взаимодействии с рецепторами, прогрессивно растут. За новыми знаниями следует расширение терапевтических возможностей и показаний к использованию гепаринов. Возникают предпосылки к созданию препаратов нового поколения с модифицированными свойствами, снижающими риск развития кровотечений при использовании с неантикоагулянтной целью. Неантикоагулянтные свойства гепаринов делают их кандидатами для патогенетического лечения пациентов с COVID-19. Данный обзор посвящен антикоагулянтным и неантикоагулянтным свойствам гепаринов, а также лежащим в их основе молекулярным механизмам.

1. Mulloy B., Hogwood J., Gray E. et al. Pharmacology of heparin and related drugs. Pharmacol Rev. 2016;68(1):76–141. https://doi.org/10.1124/pr.115.011247.

2. Shriver Z., Capila I., Venkataraman G., Sasisekharan R. Heparin and heparan sulfate: analyzing structure and microheterogeneity. Handb Exp Pharmacol. 2012;(207):159–76. https://doi.org/10.1007/978-3-642-23056-1_8.

3. Smith S.A., Morrissey J.H. Heparin is procoagulant in the absence of antithrombin. Thromb Haemost. 2008;100(1):160–2. https://doi.org/10.1160/TH08-05-0275.

4. Oduah E.I., Linhardt R.J., Sharfstein S.T. Heparin: past, present, and future. Pharmaceuticals (Basel). 2016;9(3):38. https://doi.org/10.3390/ph9030038.

5. Bertini S., Fareed J., Madaschi L. et al. Characterization of PF4-heparin complexes by photon correlation spectroscopy and zeta potential. Clin Appl Thromb Hemost. 2017;23(7):725–34. https://doi.org/10.1177/1076029616685430.

6. Walenga J.M., Lyman G.H. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):1–18. https://doi.org/10.1016/j.critrevonc.2013.06.007.

7. Laporte S., Liotier J., Bertoletti L. et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. J Thromb Haemost. 2011;9(3):464–72. https://doi.org/10.1111/j.1538-7836.2011.04182.x.

8. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S– 94S. https://doi.org/10.1378/chest.119.1_suppl.64s.

9. Sculpher M.J., Lozano-Ortega G., Sambrook J. et al. Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J. 2009;157(5):845–52. https://doi.org/10.1016/j.ahj.2009.02.017.

10. Cassinelli G., Naggi A. Old and new applications of non-anticoagulant heparin. Int J Cardiol. 2016;212(Suppl):S14–21. https://doi.org/10.1016/S0167-5273(16)12004-2.

11. Quinsey N.S., Whisstock J.C., Le Bonniec B. et al. Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide. J Bioll Chem. 2002;277(18):15971–8. https://doi.org/10.1074/jbc.M108131200.

12. Cassinelli G., Torri G., Naggi A. Non-anticoagulant heparins as heparanase inhibitors. Adv Exp Med Biol. 2020;1221:493–522. https://doi.org/10.1007/978-3-030-34521-1_20.

13. Cole G.J., Loewy A., Glaser L. Neuronal cell–cell adhesion depends on interactions of N-CAM with heparin-like molecules. Nature. 1986;320(6061):445–7. https://doi.org/10.1038/320445a0.

14. Klebe R.J., Escobedo L.V., Bentley K.L., Thompson L.K. Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans. Cell Motil Cytoskeleton. 1986;6(3):273–81. https://doi.org/10.1002/cm.970060304.

15. Sandset P.M., Abildgaard U., Larsen M.L. Heparin induces release of extrinsic: coagulation pathway inhibitor (EPI). Thromb Res. 1988;50(6):803–13. https://doi.org/10.1016/0049-3848(88)90340-4.

16. Webb L., Ehrengruber M.U., Clark-Lewis I. et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci U S A. 1993;90(15):7158–62. https://doi.org/10.1073/pnas.90.15.7158.

17. Wildhagen K.C., de Frutos P.C., Reutelingsperger C.P. et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014;123(7):1098–101. https://doi.org/10.1182/blood-2013-07-514984.

18. Chang G.M., Atkinson H.M., Berry L.R., Chan A.K. Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin, and a covalent antithrombin–heparin complex. Blood Coagul Fibrinolysis. 2017;28(6):431–7. https://doi.org/10.1097/MBC.0000000000000611.

19. Lam L., Silbert J., Rosenberg R. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun. 1976;69(2):570–7. https://doi.org/10.1016/0006-291x(76)90558-1.

20. Friedl A., Filla M., Rapraeger A.C. Tissue-specific binding by FGF and FGF receptors to endogenous heparan sulfates. Methods Mol Biol. 2001;171:535–46. https://doi.org/10.1385/1-59259-209-0:535.

21. Li J., Guo Z.Y., Gao X.H. et al. Low molecular weight heparin (LMWH) improves peritoneal function and inhibits peritoneal fibrosis possibly through suppression of HIF-1, VEGF and TGF-1. PLoS One. 2015;10(2):e0118481. https://doi.org/10.1371/journal.pone.0118481.

22. Yang Y., Long Y., Wang Y. et al. Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles. Int J Pharm. 2020;577:119085. https://doi.org/10.1016/j.ijpharm.2020.119085.

23. Sanford D., Naidu A., Alizadeh N., Lazo-Langner A. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2014;12(7):1076–85. https://doi.org/10.1111/jth.12595.

24. Ettelaie C., Fountain D., Collier M.E.W. et al. Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-B. Biochim Biophys Acta. 2011;1812(12):1591–600. https://doi.org/10.1016/j.bbadis.2011.09.007.

25. Alonso D., Bertolesi G., Farias E. et al. Antimetastatic effects associated with anticoagulant properties of heparin and chemically modified heparin species in a mouse mammary tumor model. Oncol Rep. 1996;3(1):219–22. https://doi.org/10.3892/or.3.1.219.

26. Koenig A., Norgard-Sumnicht K., Linhardt R., Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101(4):877–89. https://doi.org/10.1172/JCI1509.

27. Ma L., Qiao H., He C. et al. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer. Invest New Drugs. 2012;30(2):508–17. https://doi.org/10.1007/s10637-010-9578-0.

28. Schlesinger M., Roblek M., Ortmann K. et al. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. Thromb Res. 2014;133(5):855–62. https://doi.org/10.1016/j.thromres.2014.02.020.

29. Joseph P.R.B., Sawant K.V., Rajarathnam K. Heparin-bound chemokine CXCL8 monomer and dimer are impaired for CXCR1 and CXCR2 activation: implications for gradients and neutrophil trafficking. Open Biol. 2017;7(11):170168. https://doi.org/10.1098/rsob.170168.

30. Gomes A.M, Kozlowski E.O., Borsig L. et al. Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: Effect on P-selectin, heparanase, metastasis and cellular recruitment. Glycobiology. 2015;25(4):386–93. https://doi.org/10.1093/glycob/cwu119.

31. Pfankuchen D.B., Baltes F., Batool T. et al. Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway. Oncotarget. 2017;8(40):67553–66. https://doi.org/10.18632/oncotarget.18738.

32. Sindrewicz P., Yates E.A., Turnbull J.E. et al. Interaction with the heparin-derived binding inhibitors destabilizes galectin-3 protein structure. Biochem Biophys Res Commun. 2020;523(2):336–41. https://doi.org/10.1016/j.bbrc.2019.12.054

33. Yu Y., Lv Q., Zhang B. et al. Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. J Cancer Res Ther. 2016;12(Suppl):37–42. https://doi.org/10.4103/0973-1482.191627.

34. Groen H.J., van der Heijden E.H., Klinkenberg T.J. et al. Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. Br J Cancer. 2019;121(5):372–7. https://doi.org/10.1038/s41416-019-0533-3.

35. Meyer G., Besse B., Doubre H. et al. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Res J. 2018;52(4). https://doi.org/10.1183/13993003.01220-2018.

36. Klerk C.P., Smorenburg S.M., Otten H.-M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130–5. https://doi.org/10.1200/JCO.2005.03.134.

37. Lee A.Y., Rickles F.R., Julian J.A. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123–9. https://doi.org/10.1200/JCO.2005.03.133.

38. Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22(10):1944–8. https://doi.org/10.1200/JCO.2004.10.002.

39. Liao W.Y., Ho C.C., Hou H.H. et al. Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer. J Pathology. 2015;235(1):50–64. https://doi.org/10.1002/path.4421.

40. Alyahya R., Sudha T., Racz M. et al. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Int J Oncol. 2015;46(3):1225–31. https://doi.org/10.3892/ijo.2014.2803.

41. Oschatz C., Maas C., Lecher B. et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity. 2011;34(2):258–68. https://doi.org/10.1016/j.immuni.2011.02.008.

42. Stelmach I., Jerzynska J., Stelmach W. et al. The effect of inhaled heparin on airway responsiveness to histamine and leukotriene D4. Allergy Asthma Proc. 2003;24(1): 59–65.

43. Vancheri C., Mastruzzo C., Armato F. et al. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol. 2001;108(5):703–8. https://doi.org/10.1067/mai.2001.118785.

44. Becker R.C., Mahaffey K.W., Yang H. et al. Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. J Thromb Thrombolysis. 2011;31(2):146–53. https://doi.org/10.1007/s11239-010-0532-y.

45. Rathbun S.W., Aston C.E., Whitsett T.L. A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. J Thromb Haemost. 2012;10(5):833–9. https://doi.org/10.1111/j.1538-7836.2012.04669.x.

46. Weiler J.M., Edens R.E., Linhardt R., Kapelanski D. Heparin and modified heparin inhibit complement activation in vivo. J Immunol. 1992;148(10):3210–5.

47. Linhardt R.J., Rice K.G., Kim Y.S. et al. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro. J Biol Chem. 1988;263(26):13090–6. https://doi.org/10.1016/S0021-9258(18)37675-0.

48. Proudfoot A.E., Fritchley S., Borlat F. et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem. 2001;276(14):10620–6. https://doi.org/10.1074/jbc.M010867200.

49. Young E., Podor T.J., Venner T., Hirsh J. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vas Biol. 1997;17(8):1568–74. https://doi.org/10.1161/01.atv.17.8.1568.

50. Brinkmann V., Reichard U., Goosmann C. et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5. https://doi.org/10.1126/science.109238.

51. Iba T., Hashiguchi N., Nagaoka I. et al. Heparins attenuated histonemediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp. 2015;3(1):36. https://doi.org/10.1186/s40635-015-0072-z.

52. Redini F., Tixier J., Petitou M. et al. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J. 1988;252(2):515–9. https://doi.org/10.1042/bj2520515.

53. von Brühl M.-L., Stark K., Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819–35. https://doi.org/10.1084/jem.20112322.

54. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26–34. https://doi.org/10.1097/CCM.0b013e3181c98d21.

55. Connor W.E., Armstrong M.L. Plasma lipoprotein lipase after subcutaneous heparin. Circulation. 1961;24(1):87–93. https://doi.org/10.1161/01.cir.24.1.87.

56. Wang L., Fuster M., Sriramarao P., Esko J.D. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nature Immunol. 2005;6(9):902–10. https://doi.org/10.1038/ni1233.

57. Kitamura N., Yamaguchi M., Shimabukuro K. et al. Heparin-like glycosaminoglycans inhibit leukocyte adhesion to endotoxin-activated human vascular endothelial cells under nonstatic conditions. Eur Surg Res. 1996;28(6):428–35. https://doi.org/10.1159/000129487.

58. Miller S.J., Hoggatt A., Faulk W.P. Heparin regulates ICAM-1 expression in human endothelial cells: an example of non-cytokine-mediated endothelial activation. Thromb Haemost. 1998;80(3):481–7.

59. Coombe D.R., Stevenson S.M., Kinnear B.F. et al. Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans: 2. Biochemical analyses. Biochemistry. 2008;47(17):4863–75. https://doi.org/10.1021/bi7024595.

60. Kiselyov V.V., Berezin V., Maar T.E. et al. The first immunoglobulin-like neural cell adhesion molecule (NCAM) domain is involved in double-reciprocal interaction with the second immunoglobulin-like NCAM domain and in heparin binding. J Biol Chem. 1997;272(15):10125–34. https://doi.org/10.1074/jbc.272.15.10125.

61. Diamond M.S., Alon R., Parkos C.A. et al. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol. 1995;130(6):1473–82. https://doi.org/10.1083/jcb.130.6.1473.

62. Hu Q.-Y., Fink E., Grant C.K., Elder J.H. Selective interaction of heparin with the variable region 3 within surface glycoprotein of laboratory-adapted feline immunodeficiency virus. PloS One. 2014;9(12):e115252. https://doi.org/10.1371/journal.pone.0115252.

63. Luan Z., Hu B., Wu L. et al. Unfractionated heparin alleviates human lung endothelial barrier dysfunction induced by high mobility group box 1 through regulation of P38–GSK3–Snail signaling pathway. Cell Physiol Biochem. 2018;46(5):1907–18. https://doi.org/10.1159/000489375.

64. Morgan M.J., Liu Z.-G. Crosstalk of reactive oxygen species and NF-B signaling. Cell Res. 2011;21(1):103–15. https://doi.org/10.1038/cr.2010.178.

65. Blaukovitch C.I., Pugh R., Gilotti A.C. et al. Heparin treatment of vascular smooth muscle cells results in the synthesis of the dual-specificity phosphatase MKP-1. J Cell Biochem. 2010;110(2):382–91. https://doi.org/10.1002/jcb.22543.

66. Stewart E., Liu X., Clark G. et al. Inhibition of smooth muscle cell adhesion and proliferation on heparin-doped polypyrrole. Acta Biomater. 2012;8(1):194–200. https://doi.org/10.1016/j.actbio.2011.07.029.

67. Achilles A., Mohring A., Zeus T. et al. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: reply. J Thromb Haemost. 2017;15(7):1524–5. https://doi.org/10.1111/jth.13595.

68. Luan Z.-G., Naranpurev M., Ma X.-C. Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation. 2014;37(3):924–32. https://doi.org/10.1007/s10753-014-9812-6.

69. Lipowsky H.H., Lescanic A. Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin. Microvasc Res. 2017;112:72–8. https://doi.org/10.1016/j.mvr.2017.03.007.

70. Floer M., Götte M., Wild M.K. et al. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol. 2010;176(1):146–57. https://doi.org/10.2353/ajpath.2010.080639.

71. Nelson A., Berkestedt I., Schmidtchen A. et al. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock. 2008;30(6):623–7. https://doi.org/10.1097/SHK.0b013e3181777da3.

72. Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5.

73. Harenberg J., Jonas J.B., Trecca E.M. A liaison between sudden sensorineural hearing loss and SARS-CoV-2 infection. Thromb Haemost. 2020;120(9):1237–9. https://doi.org/10.1055/s-0040-1714370.

74. Zhou P., Yin J.-X., Tao H.-L., Zhang H.-W. Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis. Clin Chim Acta. 2020;504:73–-80. https://doi.org/10.1016/j.cca.2020.02.002.

75. Cuker A., Arepally G.M., Chong B.H. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–92. https://doi.org/10.1182/bloodadvances.2018024489.

76. Lefkou E., Khamashta M., Hampson G., Hunt B. Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus. 2010;19(1):3–12. https://doi.org/10.1177/0961203309353171.

77. Schindewolf M., Paulik M., Kroll H. et al. Low incidence of heparin-induced skin lesions in orthopedic surgery patients with low-molecularweight heparins. Clin Exp Allergy. 2018;48(8):1016–24. https://doi.org/10.1111/cea.13159.

78. Долгушина Н., Макацария А. Низкомолекулярные гепарины в лечении плацентарной недостаточности и других осложнений беременности у больных вирусными инфекциями. АГ-инфо. 2007;(3):5–1.